Fulgent Genetics Chief Scientific Officer Gao Hanlin Sells 1,645 Shares at $19.67

Executive Officer Share Activity at Fulgent Genetics

Gao Hanlin, serving as Chief Scientific Officer of Fulgent Genetics, Inc., engaged in a securities transaction on July 26, 2026, according to regulatory disclosures filed with the SEC. The transaction involved the disposition of 1,645 common shares at a price of $19.67 per share. This activity represents a routine adjustment to Hanlin's beneficial ownership position in the company and falls within the scope of officer reporting requirements under Section 16 of the Securities Exchange Act of 1934.

The sale was executed as a share withholding arrangement, a common mechanism used to satisfy tax obligations arising from equity compensation vesting events. This type of transaction allows company officers and employees to settle tax liabilities without requiring a separate cash outlay, streamlining the process of managing restricted stock unit vesting. The filing documents this activity with detailed transaction information, including the specific date, quantity of shares, and per-share price.

Tax Withholding Origins and Merger-Related Equity Compensation

The share withholding obligation disclosed in this filing traces its origins to restricted stock units that were assumed by Fulgent Genetics pursuant to an Agreement and Plan of Merger dated November 7, 2022. The merger agreement, which included FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and listed stockholders, resulted in the transfer of equity awards to Hanlin. These assumed restricted stock units were originally reported to the SEC on November 9, 2022, establishing the baseline for subsequent vesting and withholding events.

Merger-related equity awards are a standard component of corporate transactions, used to retain key executives and ensure continuity of leadership through transition periods. In this case, the assumption of restricted stock units represented a mechanism to preserve Hanlin's equity compensation rights following the merger. The vesting of these units over time creates tax obligations for the recipient, which are typically satisfied through share withholding arrangements that reduce the net number of shares received by the executive.

Beneficial Ownership Position Following Transaction

Following the disposition of 1,645 shares, Gao Hanlin maintains direct beneficial ownership of 988,729 common shares of Fulgent Genetics, Inc. This substantial shareholding reflects Hanlin's significant equity stake in the company and ongoing alignment with shareholder interests. The disclosure confirms that all 988,729 shares are held in direct form, meaning Hanlin has full ownership and voting rights without any intermediate holding entities.

The retained ownership position demonstrates continued confidence in Fulgent Genetics and its strategic direction. For investors monitoring insider shareholding patterns, the scale of Hanlin's beneficial ownership is notable and may be viewed as an indicator of management commitment to the company's long-term success. Executive ownership stakes often receive attention from investors and analysts as a metric of management alignment with shareholder value creation.

Transaction Details and Share Price Context

The share withholding transaction occurred at a per-share price of $19.67, according to the regulatory disclosure. This price point represents the market valuation at which the tax withholding obligation was settled on July 26, 2026. The filing provides precise transaction documentation, including the transaction code designation and the specific number of shares involved, enabling investors and analysts to understand the mechanics of the executive compensation adjustment.

The immediate share price impact was not clear from available public information. However, the scale of the transaction—1,645 shares—is relatively modest in relation to typical trading volumes and the company's overall market capitalization. Tax-related share withholding arrangements are routine corporate events that generally do not signal material strategic developments or changes in management's confidence in the company's prospects.

Regulatory Framework for Officer and Director Disclosures

Fulgent Genetics executives and directors are required to report changes in beneficial ownership pursuant to Section 16(a) of the Securities Exchange Act of 1934. This regulatory framework, commonly referred to as "Section 16" reporting, mandates disclosure of transactions by officers, directors, and 10 percent shareholders. The reporting requirement serves to promote transparency regarding insider transactions and provides investors with timely information about executive and director trading activity.

Form 4 filings are the primary mechanism through which insiders report changes in beneficial ownership. These filings must be submitted to the SEC within two business days of the transaction date. The detailed disclosure requirements include transaction date, securities class, quantity, price, and the resulting beneficial ownership position. Compliance with these disclosure obligations is mandatory, and material misstatements or omissions can result in federal criminal penalties. Hanlin's filing was executed on July 28, 2026, in accordance with these regulatory timelines.

Fulgent Genetics Context and Corporate Structure

Fulgent Genetics, Inc. operates as a NASDAQ-listed company focused on genetic testing and genomic analysis services. The company's Chief Scientific Officer role, held by Gao Hanlin, represents a senior leadership position responsible for scientific strategy, research direction, and technical oversight of the company's testing platforms and services. The position typically involves direct involvement in product development, clinical validation, and scientific advisory functions within the organization.

The company's 2022 merger, which forms the basis for Hanlin's restricted stock unit awards, represented a significant corporate transaction that integrated Fulgent Pharma Holdings, Inc. into the parent company structure. This type of consolidation often results in equity compensation arrangements designed to retain key technical and managerial talent during and after the integration process. The ongoing vesting of merger-related equity awards continues to impact executive compensation structures and insider shareholding patterns.

Insider Shareholding as Investment Signal

Investors and analysts frequently examine insider shareholding patterns and transactions as potential indicators of management confidence in company prospects. When executives maintain substantial equity positions or acquire additional shares, this activity may suggest positive sentiment regarding future performance. Conversely, significant selling activity by senior management can sometimes generate heightened scrutiny regarding management's outlook on near-term business performance, though individual transactions driven by personal financial or tax management considerations may not carry such implications.

In Hanlin's case, the transaction under review represents a tax-motivated share withholding event rather than a discretionary sale decision. The filing documentation explicitly establishes that the shares were withheld to satisfy tax obligations arising from equity vesting, rather than a voluntary market sale decision. This distinction is important for investors interpreting the transaction's significance, as it suggests the activity reflects tax planning mechanics rather than a shift in management's confidence or investment perspective.

Documentation and Filing Compliance

The regulatory filing submitted by Gao Hanlin includes comprehensive documentation of the transaction and ownership position. The filing was signed on July 28, 2026, with Paul Kim executing the document as attorney-in-fact on behalf of the reporting person. This authorization structure allows corporate officers to delegate the administrative responsibility for Section 16 filings to legal counsel or other representatives while maintaining the authenticity and legal responsibility of the disclosure.

The form includes detailed response explanations referencing the original November 2022 merger agreement and the prior Form 4 filing reporting the initial assumption of restricted stock units. This cross-referencing ensures that investors and regulators can trace the historical context of the equity awards and understand the relationship between the current transaction and earlier merger-related compensation arrangements. Compliance with SEC documentation standards requires this level of detail to maintain the integrity and transparency of insider trading disclosures.